Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.51

+0.9%

2:35 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (3654)	5/7/2001 11:43:04 AM
From: JOEBT1	Read Replies (1) of 52153

Peter--Re:-CEGE cancer vaccine CEGE's prostrate and pancreatic cancer trials used non patient specific vaccine. In their lung cancer trial they are using patient specific vaccine. I totally agree with you on the difficulties associated with getting approval for patient specific vaccines, however CEGE's goal is to use only non specific vaccines. They have restarted the prostrate cancer trial with a more potent (5 to 10 times) version of their GVAX vaccine. The new version is non specific as was the older GVAX. I've looked at this several times over the years and have decided to "nibble" and maybe "bite" because of upcoming ASCO report. Their cash and ABGX stock value is about 80% of their market value. Joe

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next